Labcorp Holdings LH Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharma Laboratory Services | $780.6M+8.2% | $793M+3.4% | $799.1M+8.3% | $784.8M+11.0% | $721.3M+1.5% | |
| Diagnostics | $2.76B+5.0% | $2.73B+5.5% | $2.77B+8.5% | $2.75B+8.9% | $2.63B+6.0% | |
| Operating Income by Business | ||||||
| Biopharma Laboratory Services | $120.7M+12.9% | $136.1M+4.1% | $132.2M+9.3% | $123.3M+14.8% | $106.9M+7.0% | |
| Corporate Segment | -$116.6M+11.9% | -$100.7M+46.7% | -$109.9M+36.3% | -$139.2M+22.8% | -$132.4M-2.7% | |
| Diagnostics | $458.7M+7.3% | $419.2M+16.6% | $450.4M+16.3% | $482.8M+9.4% | $427.5M+2.3% | |
| Percent of Revenue Contributed by Business | ||||||
| Biopharma Laboratory Services | 22%0.0pp | —— | 22%0.0pp | 22%0.0pp | 22%0.0pp | |
| Diagnostics | 78%0.0pp | —— | 78%0.0pp | 78%0.0pp | 78%0.0pp | |
| Other Cost and Expense, Operating by Business | ||||||
| Biopharma Laboratory Services | $89.7M-0.3% | $90.8M-3.8% | $102.8M+15.5% | $101.2M+16.1% | $90M-7.7% | |
| Diagnostics | $438M+1.8% | $446M+4.5% | $462.8M+11.1% | $454.2M+12.6% | $430.2M+12.0% | |
| Goodwill acquired, excluding measurement period adjustments by Business | ||||||
| Biopharma Laboratory Services | $0— | $0— | $0— | —— | —— | |
| Diagnostics | $146.6M— | $107.9M+10.5% | $138.8M+42.2% | —— | —— | |
| Accounts Receivable, before Allowance for Credit Loss by Business | ||||||
| Biopharma Laboratory Services | $808.4M+6.6% | $791.2M+8.5% | $747M— | $750.1M— | $758.6M— | |
| Diagnostics | $1.51B+7.8% | $1.35B+7.1% | $1.4B+5.7% | $1.41B+5.9% | $1.4B+11.3% | |
| Foreign currency impact and other adjustments to goodwill by Business | ||||||
| Biopharma Laboratory Services | -$9M— | $4.4M+129% | —— | —— | —— | |
| Diagnostics | $28.1M— | —— | $27.3M+207% | —— | —— | |
| Labor and Related Expense by Business | ||||||
| Biopharma Laboratory Services | $309.3M+6.8% | $315.8M+6.7% | $313.8M+7.1% | $302.3M+5.8% | $289.7M-0.2% | |
| Diagnostics | $1.19B+5.7% | $1.21B+3.8% | $1.2B+4.7% | $1.16B+7.7% | $1.12B+6.4% | |
| Supplies Expense by Business | ||||||
| Biopharma Laboratory Services | $121.5M+9.4% | $117.1M-4.2% | $119.5M+9.1% | $130.8M+22.6% | $111.1M+7.3% | |
| Diagnostics | $613.5M+4.6% | $589.7M+4.0% | $589.4M+9.5% | $591.3M+8.6% | $586.6M+4.7% | |
| Goodwill by Business | ||||||
| Biopharma Laboratory Services | $1.35B— | $1.35B+6.9% | $1.35B— | $1.39B— | —— | |
| Diagnostics | $5.61B— | $5.43B+6.5% | $5.33B— | $5.17B— | —— | |
| Depreciation by Business | ||||||
| Biopharma Laboratory Services | $28.6M0.0% | $29.4M-0.7% | $29M-7.9% | $29M-4.3% | $28.6M-8.3% | |
| Diagnostics | $63.8M+3.4% | $65.3M-5.5% | $66.4M+2.0% | $65.4M+3.6% | $61.7M0.0% | |
| Percent of Revenue Contributed by Geography | ||||||
| Europe | 10%+1.0pp | —— | 9%0.0pp | 9%0.0pp | 9%0.0pp | |
| North America | 86%-1.0pp | —— | 87%0.0pp | 87%0.0pp | 87%0.0pp | |
| Other countries | 4%0.0pp | —— | 4%0.0pp | 4%0.0pp | 4%0.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Labcorp Holdings break its business down?
- Labcorp Holdings (LH) reports revenue by business across 2 parts — Biopharma Laboratory Services and Diagnostics. Each is extracted from the segment footnotes and tracked over time.
- Where does Labcorp Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Labcorp Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
